Dickson R B, Johnson M D, Maemura M, Low J
Lombardi Cancer Research Center, Georgetown University, Washington, DC, USA.
Breast Cancer Res Treat. 1996;38(1):121-32. doi: 10.1007/BF01803790.
Most of the pharmaceuticals in clinical practice today for treatment of breast and other cancers are cytotoxic or cytostatic inhibitors of tumor growth. While this type of drug has found its place, along with surgery and radiotherapy, in treatment of disease, the breast cancer death rate has not decreased. This appears to be the result of rising incidence, resistance to therapy, and metastasis of the disease. Since distant metastasis (usually indicated by lymph node involvement) of breast cancer is related only indirectly to tumor size, it would appear that a concerted effort should be made to discover drugs which directly interfere with this complex process. Metastasis appears to depend upon tumor cell motility, dedifferentiation, local invasion, and angiogenesis. Significant progress has been recently made in the creation of new animal models of metastasis and in identifying several new drugs which may be suitable for clinical inhibition of this process. This article reviews current findings on anti-invasion/metastasis drugs with a focus on breast cancer.
当今临床实践中用于治疗乳腺癌和其他癌症的大多数药物都是细胞毒性或细胞生长抑制性的肿瘤生长抑制剂。虽然这类药物与手术和放疗一起在疾病治疗中占据了一席之地，但乳腺癌的死亡率并未下降。这似乎是发病率上升、对治疗产生耐药性以及疾病转移的结果。由于乳腺癌的远处转移（通常通过淋巴结受累来表明）仅与肿瘤大小间接相关，因此似乎应该齐心协力去发现能够直接干扰这一复杂过程的药物。转移似乎取决于肿瘤细胞的运动性、去分化、局部侵袭和血管生成。最近在创建新的转移动物模型以及鉴定几种可能适用于临床抑制这一过程的新药方面取得了重大进展。本文综述了抗侵袭/转移药物的当前研究结果，重点是乳腺癌。
